Loading stock data…
IDXX
$567.46+6.66 (+1.19%)
Market ClosedLast close May 1
IDEXX Laboratories, Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
IDEXX Laboratories, Inc. in the Healthcare sector is trading at $567.46. The stock is currently 26% below its 52-week high of $769.98, remaining 11.5% below its 200-day moving average. Technical signals show neutral RSI of 48 and bullish MACD crossover, explaining why IDXX maintains its current current market pressure. The Whystock Score of 70/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 48) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$567.46
Potential Downside
31.5%
Whystock Fair Value$388.89
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus14 analysts
Buy
Mean target$724.50+27.7%
Range$470.00 – $823.00
Fundamentals
IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Co...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$46.05B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
44.18
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.72
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
61.40%
Volume
Today's trading volume
591,657
Recent News
Here's How IDEXX Laboratories Is Placed Ahead of Q1 Earnings
IDXX heads into Q1 earnings with strong growth forecasts, steady estimate beats, and momentum in diagnostics and recurring revenue streams.
What Analyst Projections for Key Metrics Reveal About Idexx (IDXX) Q1 Earnings
Beyond analysts' top-and-bottom-line estimates for Idexx (IDXX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Idexx Laboratories (IDXX) Reports Next Week: Wall Street Expects Earnings Growth
Idexx (IDXX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will DXCM's G7 Uptake Continue to Drive Top-line Growth in Q1?
DexCom's Q1 results may see strong growth from G7 uptake and CGM demand, but pricing mix and rising investments could weigh on margins.
What You Need to Know Ahead of IDEXX Laboratories' Earnings Release
IDEXX Laboratories is ready to release its fiscal first-quarter earnings next month, and analysts project a double-digit profit growth.